FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080874810> ?p ?o ?g. }

• W2080874810 endingPage "745" @default.
• W2080874810 startingPage "745" @default.
• W2080874810 abstract "Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy Monica Baiula,1 Andrea Bedini,1 Jacopo Baldi,1 Megan E Cavet,2 Paolo Govoni,3 Santi Spampinato11Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy; 2Global Pharmaceutical R&D, Bausch & Lomb Inc., Rochester, NY, USA; 3Department of Biomedical, Biotechnological and Translational Sciences, University of Parma, Parma, ItalyBackground: Mapracorat, a novel nonsteroidal selective glucocorticoid receptor agonist, has been proposed for the topical treatment of inflammatory disorders as it binds with high affinity and selectivity to the human glucocorticoid receptor and displays a potent anti-inflammatory activity, but seems to be less effective in transactivation of a number of genes, resulting in a lower potential for side effects. Contrary to classical glucocorticoids, mapracorat displays a reduced ability to increase intraocular pressure and in inducing myocilin, a protein linked to intraocular pressure elevation. Allergic conjunctivitis is the most common form of ocular allergy and can be divided into an early phase, developing immediately after allergen exposure and driven primarily by mast cell degranulation, and a late phase, developing from 6–10 hours after the antigen challenge, and characterized by conjunctival infiltration of eosinophils and other immune cells as well as by the production of cytokines and chemokines.Methods: In this study, mapracorat was administered into the conjunctival sac of ovalbumin (OVA)-sensitized guinea pigs 2 hours after the induction of allergic conjunctivitis, with the aim of investigating its activity in reducing clinical signs of the late-phase ocular reaction and to determine its mechanism of anti-allergic effects with respect to apoptosis of conjunctival eosinophils and expression of the chemokines C-C motif ligand 5 (CCL5), C-C motif ligand 11 (CCL11), and interleukin-8 (IL-8) and the proinflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α).Results: Mapracorat, administered into the conjunctival sac of OVA-sensitized guinea pigs 2 hours after allergen exposure, was effective in reducing clinical signs, eosinophil infiltration, and eosinophil peroxidase activity in the guinea pig conjunctiva; furthermore, it reduced conjunctival mRNA levels and protein expression of both CCL5 and CCL11. Mapracorat was more effective than dexamethasone in increasing, in conjunctival sections of OVA-treated guinea pigs, apoptotic eosinophils.Conclusion: Mapracorat displays anti-allergic properties in controlling the late phase of ocular allergic conjunctivitis and is a promising candidate for the topical treatment of allergic eye disorders.Keywords: allergic conjunctivitis, late-phase response, eosinophil" @default.
• W2080874810 created "2016-06-24" @default.
• W2080874810 creator A5013228218 @default.
• W2080874810 creator A5056093010 @default.
• W2080874810 creator A5071547436 @default.
• W2080874810 creator A5073074936 @default.
• W2080874810 creator A5081760630 @default.
• W2080874810 creator A5088424229 @default.
• W2080874810 date "2014-06-01" @default.
• W2080874810 modified "2023-09-23" @default.
• W2080874810 title "Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy" @default.
• W2080874810 cites W1495764983 @default.
• W2080874810 cites W1524223037 @default.
• W2080874810 cites W1524457746 @default.
• W2080874810 cites W1530640702 @default.
• W2080874810 cites W1534102668 @default.
• W2080874810 cites W1536300493 @default.
• W2080874810 cites W1605768991 @default.
• W2080874810 cites W1935322656 @default.
• W2080874810 cites W1965035719 @default.
• W2080874810 cites W1972464908 @default.
• W2080874810 cites W1978410497 @default.
• W2080874810 cites W1990778958 @default.
• W2080874810 cites W1994042661 @default.
• W2080874810 cites W2002372722 @default.
• W2080874810 cites W2007990824 @default.
• W2080874810 cites W2009679749 @default.
• W2080874810 cites W2011382880 @default.
• W2080874810 cites W2015800406 @default.
• W2080874810 cites W2017916832 @default.
• W2080874810 cites W2020632674 @default.
• W2080874810 cites W2020848225 @default.
• W2080874810 cites W2022665762 @default.
• W2080874810 cites W2032382363 @default.
• W2080874810 cites W2039955774 @default.
• W2080874810 cites W2052806182 @default.
• W2080874810 cites W2056655687 @default.
• W2080874810 cites W2061074454 @default.
• W2080874810 cites W2064095640 @default.
• W2080874810 cites W2065389394 @default.
• W2080874810 cites W2065890957 @default.
• W2080874810 cites W2067181732 @default.
• W2080874810 cites W2074371965 @default.
• W2080874810 cites W2075560787 @default.
• W2080874810 cites W2091806298 @default.
• W2080874810 cites W2100246452 @default.
• W2080874810 cites W2102847145 @default.
• W2080874810 cites W2104952424 @default.
• W2080874810 cites W2106471110 @default.
• W2080874810 cites W2109918049 @default.
• W2080874810 cites W2118216440 @default.
• W2080874810 cites W2121416194 @default.
• W2080874810 cites W2123578268 @default.
• W2080874810 cites W2138302361 @default.
• W2080874810 cites W2152384213 @default.
• W2080874810 cites W2161297561 @default.
• W2080874810 cites W2164942621 @default.
• W2080874810 cites W2167522099 @default.
• W2080874810 cites W2170311808 @default.
• W2080874810 cites W2171151613 @default.
• W2080874810 cites W2171414808 @default.
• W2080874810 cites W2324057795 @default.
• W2080874810 cites W2468818396 @default.
• W2080874810 doi "https://doi.org/10.2147/dddt.s62659" @default.
• W2080874810 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4061172" @default.
• W2080874810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24959069" @default.
• W2080874810 hasPublicationYear "2014" @default.
• W2080874810 type Work @default.
• W2080874810 sameAs 2080874810 @default.
• W2080874810 citedByCount "15" @default.
• W2080874810 countsByYear W20808748102015 @default.
• W2080874810 countsByYear W20808748102017 @default.
• W2080874810 countsByYear W20808748102019 @default.
• W2080874810 countsByYear W20808748102020 @default.
• W2080874810 countsByYear W20808748102021 @default.
• W2080874810 countsByYear W20808748102022 @default.
• W2080874810 countsByYear W20808748102023 @default.
• W2080874810 crossrefType "journal-article" @default.
• W2080874810 hasAuthorship W2080874810A5013228218 @default.
• W2080874810 hasAuthorship W2080874810A5056093010 @default.
• W2080874810 hasAuthorship W2080874810A5071547436 @default.
• W2080874810 hasAuthorship W2080874810A5073074936 @default.
• W2080874810 hasAuthorship W2080874810A5081760630 @default.
• W2080874810 hasAuthorship W2080874810A5088424229 @default.
• W2080874810 hasBestOaLocation W20808748101 @default.
• W2080874810 hasConcept C126322002 @default.
• W2080874810 hasConcept C170493617 @default.
• W2080874810 hasConcept C203014093 @default.
• W2080874810 hasConcept C207480886 @default.
• W2080874810 hasConcept C2775984611 @default.
• W2080874810 hasConcept C2776042228 @default.
• W2080874810 hasConcept C2776946954 @default.
• W2080874810 hasConcept C2777037409 @default.
• W2080874810 hasConcept C2778938600 @default.
• W2080874810 hasConcept C2780841215 @default.
• W2080874810 hasConcept C2780870513 @default.
• W2080874810 hasConcept C59493245 @default.
• W2080874810 hasConcept C71924100 @default.

• next